Initiation of Research Coverage
Singer Capital Markets initiated equity research coverage on Solvonis Therapeutics.
Select text to share a quote on X · sign in to keep highlights & notes in your SVNS notes
Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is pleased to announce that Singer Capital Markets ("Singers") has today initiated equity research coverage (the "Initiation Note") on the Company.
The Initiation Note, titled "Psyching up for success", has been authored by Dr. Karl Keegan, Head of Life Sciences Research at Singers.
The research note is currently available to eligible institutional investors and will be made publicly available via Singers next week.
About Reach announcements
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.